Ficlatuzumab is a humanized monoclonal antibody designed for the treatment of cancers.[1]

It is a humanized monoclonal antibody that binds to hepatocyte growth factor, thus inhibiting the c-MET receptor signaling cascade.[2]

Ficlatuzumab was developed by AVEO Pharmaceuticals. In May 2012, AVEO released results of a Phase II clinical trial comparing gefitinib alone and in combination with ficlatuzamab in treatment-naive Asian patients with non-small cell lung cancer.[3]

References

  1. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ficlatuzumab" (PDF). American Medical Association.
  2. ^ Panahi Y, Mohammadzadeh AH, Behnam B, Orafai HM, Jamialahmadi T, Sahebkar A (2021). "A Review of Monoclonal Antibody-Based Treatments in Non-small Cell Lung Cancer". Reviews on New Drug Targets in Age-Related Disorders. Advances in Experimental Medicine and Biology. Vol. 1286. pp. 49–64 (57). doi:10.1007/978-3-030-55035-6_3. ISBN 978-3-030-55034-9. PMID 33725344. S2CID 232261340.
  3. ^ "AVEO Releases Phase 2 Data", Drug Discovery & Development, dddmag.com, May 3, 2012, retrieved June 3, 2012


Allikas: https://en.wikipedia.org/wiki/Ficlatuzumab
No tags for this post.